アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg - ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or candida infections. ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. coadministration of a number of cyp3a4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 2 g in 100 g - ketoconazole foam, 2% is indicated for the topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. limitations of use safety and efficacy of ketoconazole foam, 2% for treatment of fungal infections have not been established. none. risk summary there are no available data on ketoconazole foam, 2% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. no reproductive studies in animals have been performed with ketoconazole foam, 2%. in animal reproduction studies with pregnant mice, rats and rabbits both embryotoxic and developmental effects (structural abnormalities) were observed following oral dosing of ketoconazole during organogenesis. assuming equivalent systemic absorption of topical and oral ketoconazole doses and a ketoconazole foam, 2% maximum recommended human dose (mrhd) of 8 grams (equivalent to 160 mg ketoconazole), embryotoxic effects were observed at 0.8 to 2.4 times the mrhd an

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ipg pharmaceuticals, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 g - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum, t. mentagrophytes and epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by candida spp. and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

rebel distributors corp - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 g - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum, t. mentagrophytes and epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by candida spp. and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg - ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. coadministration of terfenadine or astemizole with ketoconazole tablets is contraindicated. (see box warning, warnings, and precautions sections.) concomitant administration of ketoconazole tablets with cisapride is contraindicated. (see box warning, warnings, and precautions sections.) concomitant administration of ketoconazole tablets with oral triazolam is contraindicated. (see precau

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

state of florida doh central pharmacy - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg - ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. coadministration of terfenadine or astemizole with ketoconazole tablets is contraindicated. (see box warning, warnings, and precautions.) concomitant administration of ketoconazole tablets with cisapride is contraindicated. (see box warning, warnings and precautions.) concomitant administration of ketoconazole tablets with oral triazolam is contraindicated. (see precautions.) ketoconazole is contrain

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

rebel distributors corp - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg - ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. coadministration of terfenadine or astemizole with ketoconazole tablets is contraindicated. (see box warning, warnings, and precautions sections.) concomitant administration of ketoconazole tablets with cisapride is contraindicated. (see box warning, warnings, and precautions sections.) concomitant administration of ketoconazole tablets with oral triazolam is contraindicated. (see precautions section

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

proficient rx lp - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 g - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum, t. mentagrophytes and epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by candida spp. and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

patriot pharmaceuticals, llc - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 ml - ketoconazole 2% shampoo is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by pityrosporum orbiculare (also known as malassezia furfur or m. orbiculare ). note: tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. treatment of the infection may not immediately result in normalization of pigment to the affected sites. normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora. ketoconazole 2% shampoo is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 ml - ketoconazole shampoo, 2% is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by pityrosporum orbiculare (also known as malassezia furfur or m. orbiculare ). note: tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. treatment of the infection may not immediately result in normalization of pigment to the affected sites. normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora. ketoconazole shampoo, 2% is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.